In recent years progress has been made in developing cancer immunotherapies that target specific aspects of an individual’s tumour.more
Introducing cancer immunotherapy
Beyond the immunity cycle
Roche’s scientists are leading pioneers in immune biology and cancer research, which is resulting in innovative and personalised treatment options in cancer.
Collaboration in research
Cancer remains one of the leading causes of death worldwide, but world-class research provides hope.more
About bladder cancer
Bladder cancer is one of the top ten most common cancers in the world.more
Bladder cancer: the symptoms you shouldn’t ignore
One patient shares his experience being diagnosed with a disease he knew nothing about.more
About lung cancer
Lung cancer has been the most common cancer in the world for several decades, accounting for 1 in 5 of all cancer deaths.more
About renal cell carcinoma
Renal cell carcinoma is the most common form of kidney cancer, accounting for approximately 90% of casesmore
A pocket guide to interpreting data
Obtain simple definitions of clinical terms with our pocket guide to interpreting data.
Learn about some of the different ways we can harness the power of our immune system to fight cancer.more
Linking T-cells and cancer cells
When the body’s own immune system fails, T-cell bispecific antibodies help T-cells spring back into action and attack cancer cells.
CEO on cancer immunotherapy
Roche CEO Severin Schwan talks about our commitment and leadership in this exciting field.
The PD-L1 pathway
The role of the immune system is to protect the body from foreign invaders. PD-L1 can help tumour cells evade the immune surveillance.
Unleashing the T-Cell army
Learn how our research and development team managed to separate 200 known cancer types into three primary immune profiles.